Delivery Order SPE2DB20D3103-SPE2DB23FM8J6
- Not listed
- This federal contract award, valued at $116,823.84, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of PADCEV 30 MG VIALS, and has an ultimate completion date of January 9, 2024. The contract is a firm fixed-price arrangement, and was not set aside for any specific business category. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
- This federal contract award, valued at $19,999.44, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of PADCEV 30 MG VIALS, a medical product, with a completion date of December 10, 2024. The contract is a Delivery Order under a Firm Fixed Price type, and there is no set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of PADCEV 30 MG VIALS. The contract is a Firm Fixed Price Delivery Order with a ceiling value of $5,543.80 and a period of performance through March 27, 2025. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $22,175.20, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PADCEV 30 MG VIALS, a pharmaceutical product, with a completion date of February 25, 2025. The contract is a Delivery Order, with a Firm Fixed Price pricing type. It is not designated as a Set-Aside contract. AmerisourceBergen Drug Corp holds a significant...
- This federal contract award, valued at $18,479.50, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PADCEV 20 MG VIALS, a pharmaceutical product, with a completion date of March 25, 2025. The contract is a Firm Fixed Price Delivery Order and was not set aside for any specific business type. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC)...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $24,988.50, is for the delivery of PADCEV 30 MG VIALS, a pharmaceutical product. This is a Firm Fixed Price delivery order contract with a period of performance through December 9, 2024. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,345.32, is for the delivery of PADCEV 30 MG VIALS, a pharmaceutical product. The contract has an ultimate completion date of January 22, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical,...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of PADCEV 30 MG VIALS, a medical product, with a ceiling value of $11,087.60 and a completion date of February 27, 2025. This award is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of PADCEV 30 MG vials, a pharmaceutical product. The contract has a ceiling value of $22,175.20 and a completion date of June 12, 2025. It is a Firm Fixed Price contract and is not set aside for any particular business type. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, with a ceiling value of $25,863.30, is for the delivery of PADCEV 30 MG VIALS, a pharmaceutical product. This delivery order falls under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FM8J6Delivery Order
This federal contract award, with a ceiling value of $14,602.98, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of PADCEV 30 MG VIALS, a pharmaceutical product, with an ultimate completion date of April 11, 2023. The contract is a Delivery Order, with a Firm Fixed Price pricing type, and was not designated under any set-aside program. Amerisourcebergen is the prime contractor for this award and holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.6k | 3/21/23 |